Repros Therapeutics (RPRX) Modifies Pivotal Androxal Protocol
Tweet
Share
E-mailGet Alerts RPRX Hot Sheet
Join SI Premium – FREE
Repros Therapeutics Inc. (Nasdaq: RPRX) has modified the pivotal protocol following additional FDA input post the May 9th meeting.
The revision included additional secondary endpoints specifying the number of men in the study that exhibit a single time point of testosterone concentration greater than 1500, 1800 and 2500 ng/dL. It is common to experience such high excursions for approved topical products. No subject in an Androxal study has ever exhibited a concentration greater than 1500 ng/dL and the maximum levels achieved are approximately 1100 ng/dL. This level occurs rarely and only in men administered the higher (25 mg) dose. The pivotal studies are designed to titrate men to greater than 450 ng/dL by first starting on the 12.5 mg dose. The Company believes 60% of men will achieve the 450 ng/dL up-titration threshold on the 12.5 mg dose resulting in 40% of men up-titrating to the 25 mg dose.
The difference in Androxal response as compared to the topical products is related to the mechanism of action of the Repros drug. Androxal® stimulates endogenous production of testosterone. Normal maximum testosterone production can reach a concentration of around 1040 ng/dL.
The revision included additional secondary endpoints specifying the number of men in the study that exhibit a single time point of testosterone concentration greater than 1500, 1800 and 2500 ng/dL. It is common to experience such high excursions for approved topical products. No subject in an Androxal study has ever exhibited a concentration greater than 1500 ng/dL and the maximum levels achieved are approximately 1100 ng/dL. This level occurs rarely and only in men administered the higher (25 mg) dose. The pivotal studies are designed to titrate men to greater than 450 ng/dL by first starting on the 12.5 mg dose. The Company believes 60% of men will achieve the 450 ng/dL up-titration threshold on the 12.5 mg dose resulting in 40% of men up-titrating to the 25 mg dose.
The difference in Androxal response as compared to the topical products is related to the mechanism of action of the Repros drug. Androxal® stimulates endogenous production of testosterone. Normal maximum testosterone production can reach a concentration of around 1040 ng/dL.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Royalty Pharma (RPRX) PT Raised to $65 at TD Cowen
- Visa to launch AI financial assistant for U.S. banks in August 2026
- Rubrik joins Internet2 to support cybersecurity in higher education
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
